Overall, these results suggest that the genetic inhibition of mPTP in the CPVT model of CASQ2 KO did not lead to overt pathological cardiac remodeling, despite some early signs of potential cardiac hypertrophy. This evidence concerns the gene CASQ2 and catecholaminergic polymorphic ventricular tachycardia.